The GLP-1 Meal Replacement Shift: What the Data Shows
Here is a number that should change how you think about new product development in food and beverage: grocery spending drops by 5.3% within six months of a consumer starting a GLP-1 drug like Ozempic, Wegovy, or Mounjaro. That finding, published by Cornell University researchers in the Journal of Marketing Research, does not describe a minor adjustment in shopping habits. It describes a structural reduction in how much food people buy.
For GLP-1 meal replacements specifically, the implications are significant. When consumers eat fewer total meals, every eating occasion carries more weight. A lunch that used to be one of three daily meals now might be one of two. The product filling that slot needs to deliver more nutrition per serving, more satiety per calorie, and a stronger reason to choose it over simply skipping the meal entirely.
This is why the GLP-1 meal replacement category is not just growing — it is being fundamentally redesigned. Brands that built their business on “diet shakes” are scrambling to reposition. New entrants like Nestle’s Vital Pursuit line are designing products from scratch around GLP-1 user needs. And the brands caught in the middle — the ones with adequate products but unvalidated claims — are the most vulnerable.
At Saucery, we use synthetic consumer validation with AI-modelled consumer personas to help F&B brands pressure-test product claims and positioning before committing to production. The GLP-1 meal replacement space is one of the most active categories we are seeing, because the stakes of getting your claims wrong are higher when consumers have fewer buying occasions to win.
GLP-1 Market Size and Adoption Rates in 2026
Before diving into specific product trends, it is worth grounding the discussion in the scale of GLP-1 adoption and what it means for the U.S. food industry.
GLP-1 drug adoption: As of early 2026, approximately 6% of U.S. adults — roughly 15.5 million people — have used a GLP-1 receptor agonist such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). Prescriptions have grown at a compound annual rate exceeding 40% since 2022. Morgan Stanley projected the GLP-1 drug market would reach $105 billion globally by 2030, up from approximately $24 billion in 2023.
Grocery spending impact: The Cornell study found the 5.3% overall decline was not evenly distributed. Calorie-dense categories — snack cakes, sugary cereals, frozen pizza — saw declines of 9-12%. But high-protein and nutrient-dense categories showed relative resilience, declining only 1-2% or in some cases growing. Meal replacements sit squarely in the “resilient” zone, particularly those with 25g+ protein per serving.
Meal replacement market size: The U.S. meal replacement market was valued at approximately $7.2 billion in 2025 and is projected to reach $10.4 billion by 2029, according to Euromonitor data. A significant portion of that growth is being attributed to GLP-1-adjacent demand — consumers who need nutrient-dense, portion-controlled options that complement their medication regimen.
Research from Purdue University’s Center for Food and Agricultural Business further confirmed these patterns, finding that GLP-1 users shift spending toward products with clear nutritional credentials — particularly those making specific protein, vitamin, and mineral claims on pack.
This is where the opportunity lies for brands. The question is not whether GLP-1 will reshape the meal replacement category. It already has. The question is which claims and formats will win the reduced number of eating occasions that remain.
We use a framework called Saucery Trends to classify demand signals into three phases: Growing Trend (early signals, under 10% category penetration), Going Mainstream (scaling behaviour, 10-40% penetration), and Available Everywhere (default choices, 40%+ penetration). Here is where GLP-1 meal replacements sit across each phase in 2026.
Growing Trend: GLP-1 Meal Replacements Designed Specifically for Drug Users
The most interesting developments are happening at the “Growing Trend” phase, where major CPG players are launching products explicitly designed for GLP-1 users rather than simply repositioning existing lines.
Nestle Vital Pursuit: The First Major GLP-1-Specific Meal Line
Nestle launched Vital Pursuit in late 2024 as the first major CPG brand to explicitly target GLP-1 medication users. The line includes frozen meals priced between $4.99 and $5.99, each formulated with high protein (27-30g per serving), added fibre, and essential vitamins and minerals that GLP-1 users commonly lack due to reduced food intake. This is not a repackaged Lean Cuisine. The formulation addresses specific nutritional gaps — B12, iron, and zinc deficiencies — that clinical literature has identified in long-term GLP-1 users.
The significance for the broader category: Nestle’s move signals to retailers that GLP-1-specific is now a legitimate shelf segment, not a marketing gimmick. Expect dedicated planograms by late 2026.
Boost Pre-Meal Drinks: Targeting the “Before” Occasion
Nestle Health Science’s Boost line has introduced pre-meal nutritional drinks designed to be consumed before a GLP-1 user’s main meal. The positioning is clever: rather than replacing a meal, these products ensure that the one meal a GLP-1 user does eat is nutritionally complete. Each serving delivers protein, fibre, and micronutrients in a 150-calorie format.
This “pre-meal” occasion is entirely new to the category. It did not exist before GLP-1 drugs created a consumer who eats less frequently but cares more about nutritional completeness per occasion.
Soylent’s Quiet Repositioning
Soylent, the original “complete nutrition” RTD brand, has not launched a GLP-1-specific product. But its existing positioning — 400 calories, 20g protein, 28 vitamins and minerals, designed as a full meal replacement — maps almost perfectly onto GLP-1 user needs. Search interest for “Soylent GLP-1” and “Soylent Ozempic” has grown steadily through 2025, suggesting consumers are discovering the fit organically.
The lesson: sometimes the right product already exists and the opportunity is in claims and messaging, not reformulation. This is exactly the kind of decision that benefits from validating front-of-pack claims before committing to a packaging run.
Going Mainstream: RTD Shakes and Protein-Forward Formats Capture GLP-1 Demand
The “Going Mainstream” phase is where the volume is. These are not GLP-1-specific products, but they are capturing GLP-1 user spending because they deliver the attributes this consumer segment prioritises: high protein, controlled portions, and convenience.
Huel Ready-to-Drink: The Nutritionally Complete Default
Huel has seen significant U.S. growth through 2025-2026, driven in part by GLP-1 users adopting it as a reliable lunch replacement. Each bottle delivers 400 calories, 34g protein, and all 26 essential vitamins and minerals. Huel’s advantage is its “nutritionally complete” claim — a claim that resonates strongly with consumers whose doctors have warned them about nutrient deficiencies on GLP-1 medications.
Huel’s U.S. revenue reportedly grew 40%+ year-over-year through 2025, with the brand noting that “weight management” was the fastest-growing usage occasion among new customers. That is a proxy for GLP-1 adoption even if Huel is not marketing directly to those users.
Fairlife Nutrition Plan: Protein as the Primary Purchase Driver
Fairlife, owned by Coca-Cola, has positioned its Nutrition Plan shakes (30g protein, 150 calories per bottle) as the go-to protein shake for weight management. The product sits in the same decision set as meal replacements for GLP-1 users, even though it is technically positioned as a supplement. Fairlife does not need to mention GLP-1 drugs — the product attributes speak directly to what those consumers need.
Fairlife’s parent brand has become the fastest-growing dairy brand in the U.S. over the past three years, with the Nutrition Plan line contributing disproportionately to that growth. It is a case study in how mainstream products can capture GLP-1 demand through attribute alignment rather than explicit targeting.
Factor Meals: The Prepared Meal Alternative
Factor (owned by HelloFresh) occupies an adjacent space worth noting. Their prepared meal delivery service — calorie-controlled, protein-forward, no cooking required — is increasingly positioned against meal replacement shakes. For GLP-1 users who still want to eat “real food” but need portion control and nutritional completeness, Factor represents the premium end of the spectrum. Their “Protein Plus” meals (40g+ protein per serving) directly target the same needs that shake brands address.
This competitive pressure from prepared meals is important context for any brand developing GLP-1 meal replacements. Your shake is not just competing with other shakes. It is competing with a $12 prepared meal that delivers a similar nutritional profile with more sensory satisfaction.
Atkins Shakes: Legacy Brands Adapting
Atkins has maintained mainstream shelf space through RTD formats and multipacks. The brand’s existing low-carb, high-protein positioning aligns with GLP-1 user needs, but the brand has been slower than competitors to update its messaging. Atkins represents a common challenge: a product that technically fits but lacks the claims language to capture GLP-1-aware shoppers scanning the shelf.
For a deeper look at how food trends move through adoption phases, see our framework guide.
Available Everywhere: Legacy Meal Replacements and the GLP-1 Repositioning Challenge
The “Available Everywhere” phase includes products that are already default choices in the category. Their challenge is not awareness but relevance: can they reposition fast enough to capture GLP-1-driven demand before newer brands take their share?
SlimFast: From Diet Brand to Nutritional Completeness
SlimFast has been the default meal replacement brand in the U.S. for decades, but its “diet shake” positioning is increasingly misaligned with GLP-1 user needs. GLP-1 users are not trying to restrict calories through willpower — the medication handles appetite suppression. What they need is nutrient density per serving. SlimFast’s reformulated High Protein line (20g protein, 24 vitamins and minerals) is an attempt to bridge this gap, but the brand’s historical association with dieting could work against it with a consumer segment that sees GLP-1 as a medical treatment, not a diet.
The repositioning challenge for SlimFast is fundamentally a claims challenge. The product may be adequate, but the front-of-pack messaging needs to shift from “weight loss” to “nutritional completeness for reduced eating occasions.” That is a testable hypothesis — and exactly the kind of claim hierarchy that concept testing can resolve before it reaches the shelf.
Premier Protein: The Accidental GLP-1 Winner
Premier Protein shakes (30g protein, 160 calories, 1g sugar) have become one of the best-selling products in the U.S. meal replacement and protein shake category. The brand did not design for GLP-1 users, but the product profile — high protein, low calorie, low sugar, convenient RTD format — is almost perfectly aligned with what GLP-1 users seek. Premier Protein’s parent company, BellRing Brands, has seen consistent double-digit revenue growth, with the stock price reflecting investor confidence in the GLP-1 tailwind.
Premier Protein’s success reinforces a key point: the brands winning in GLP-1 meal replacements are not necessarily the ones mentioning GLP-1. They are the ones whose nutritional profile and claims match the specific needs of a consumer eating fewer, more deliberate meals.
How GLP-1 Drugs Are Shifting Category Spending Patterns
The Cornell research and subsequent studies from Purdue and JPMorgan paint a detailed picture of how GLP-1 adoption reshapes the grocery basket:
- Overall grocery spend: Down 5.3% within 6 months of GLP-1 adoption
- Calorie-dense snacks and sweets: Down 9-12%
- Sugary beverages: Down 7-10%
- Frozen meals (non-premium): Down 6-8%
- High-protein products: Down only 1-2%, with some sub-segments growing
- Meal replacements and nutrition shakes: Growing 3-5% among GLP-1 user households
- Fresh produce and lean proteins: Relatively stable or slight growth
The pattern is clear: GLP-1 users do not stop buying food. They stop buying food that exists primarily for taste or convenience without nutritional justification. Products that can articulate a clear nutritional purpose — protein per serving, vitamin completeness, satiety per calorie — are resilient or growing.
This has direct implications for how brands should position their products. A claim like “delicious chocolate flavour” is less effective with this segment than “30g protein plus 100% daily value of 12 essential vitamins.” The nutritional credential is the primary purchase driver; taste is the secondary qualifier.
For brands tracking high-protein product patterns, the GLP-1 effect is accelerating trends that were already in motion.
Why Claims Matter More When Calories Matter Less
Here is the strategic insight that most brands are missing: GLP-1 does not just change what consumers buy. It changes how they decide.
When a consumer on Wegovy or Mounjaro stands in front of the meal replacement shelf, they are making a higher-stakes decision than the average shopper. They might only eat two meals today instead of three. They know their doctor is concerned about protein intake and micronutrient gaps. They have probably read articles about muscle loss on GLP-1 drugs.
In this context, front-of-pack claims become the primary decision filter. Not brand loyalty, not price sensitivity, not flavour variety — claims. Specifically:
- Protein quantity: “30g protein” beats “high protein” because specificity signals credibility
- Nutritional completeness: “26 essential vitamins and minerals” outperforms “fortified with vitamins”
- Portion clarity: “Complete meal in one bottle” wins against “meal replacement shake” for GLP-1 users who need to maximise every eating occasion
- Medical adjacency: Claims that reference “nutritional gaps” or “essential nutrients” resonate more than weight-loss language with consumers who already have appetite suppression handled
This is not speculation. When we run claim hierarchy experiments using AI-modelled consumer personas through Saucery’s synthetic consumer validation platform, we consistently see that specific, quantified nutritional claims outperform generic benefit claims by 15-30% in purchase intent — and the gap widens among health-motivated consumer segments.
The practical implication: if you are launching or repositioning a meal replacement product for the GLP-1 opportunity, testing your claim hierarchy is not optional. The difference between “high protein shake” and “30g complete protein with 26 essential vitamins” could be a 20-point swing in purchase intent. That is not a branding nuance. That is a launch-or-kill decision.
Understanding the science behind AI personas and research accuracy can help teams build confidence in these synthetic validation methods.
How to Validate GLP-1 Meal Replacement Claims Before Launch
Traditional consumer research takes 6-8 weeks and costs $15,000-$40,000 per study. In a category moving as fast as GLP-1 meal replacements, that timeline is a competitive disadvantage. By the time your focus group results come back, a competitor may have already launched.
Saucery’s synthetic consumer validation approach uses AI-modelled consumer personas to test product claims, positioning, and concept appeal in hours rather than weeks. Here is how F&B teams are using it for GLP-1 meal replacement development:
Claim hierarchy testing: Test 3-5 front-of-pack claims against each other to identify which drives the strongest purchase intent. For a GLP-1 meal replacement, you might test: “30g Complete Protein” vs. “Nutritionally Complete Meal” vs. “Designed for GLP-1 Users” vs. “Doctor-Recommended Nutrition” vs. “All Essential Vitamins & Minerals.”
Format extension validation: Should your GLP-1 meal replacement be an RTD shake, a powder, a frozen meal, or a bar? Each format carries different expectations. Testing format preferences with your target consumer profile prevents expensive bets on the wrong form factor.
Positioning validation: Is your product a “meal replacement,” a “nutritional shake,” a “complete meal,” or a “GLP-1 companion”? The category language is still being established, which means the positioning you choose will shape how consumers categorise your product.
The stage-gate process for consumer validation ensures these decisions are tested at the right point in your development cycle — before you have committed to packaging, manufacturing, and distribution.
Portfolio Decisions: Where to Invest in GLP-1 Meal Replacements Now
Based on the trend data and category dynamics outlined above, here are the actionable portfolio implications for F&B brands:
If you already have a meal replacement product: Your highest-ROI move is claims testing. The product may already be adequate for GLP-1 users, but your messaging probably is not. Test a GLP-1-relevant claim hierarchy and update your front-of-pack before investing in reformulation.
If you are entering the category: Avoid the “me too” RTD shake. The mainstream segment is already crowded with Huel, Fairlife, and Premier Protein. The white space is in GLP-1-specific formulations (addressing documented nutritional deficiencies), pre-meal formats (the occasion Nestle’s Boost is pioneering), or premium prepared meals that compete on sensory experience rather than convenience alone.
If you are in an adjacent category (protein bars, snacks, supplements): The GLP-1 effect is compressing eating occasions, which means your product may be competing directly with meal replacements even if it was not designed to. Test whether your product can credibly claim a “meal replacement” positioning for GLP-1 users. The search growth patterns we see in plant-based snacks suggest consumers are already making these cross-category substitutions.
What to avoid: Do not launch a GLP-1 meal replacement positioned primarily on weight loss. GLP-1 users already have appetite suppression. They need nutritional completeness, not calorie restriction. Brands that lead with “low calorie” instead of “nutritionally complete” are solving yesterday’s problem.
The GLP-1 meal replacement opportunity is real, growing, and time-sensitive. The brands that will win are not necessarily the ones with the best formulations. They are the ones that identify the right claims, validate them with real consumer data, and get to shelf before the category norms are set.
Run your own claims validation experiment at saucery.ai — results in hours, not weeks.